{"id":"placebo-for-guselkumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (guselkumab) by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. Placebos are essential for blinded, randomized controlled trials to isolate the true therapeutic benefit of the investigational agent.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:12.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT05272150","phase":"PHASE3","title":"Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-13","conditions":"Plaque Psoriasis, Scalp Psoriasis","enrollment":213},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06039189","phase":"PHASE3","title":"Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-24","conditions":"Moderate Plaque Psoriasis","enrollment":338},{"nctId":"NCT04633447","phase":"PHASE2","title":"A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-10","conditions":"Giant Cell Arteritis","enrollment":53},{"nctId":"NCT04394936","phase":"NA","title":"An Explorative Psoriasis Biomarker Study","status":"TERMINATED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2020-09-01","conditions":"Psoriasis Vulgaris","enrollment":37},{"nctId":"NCT05004727","phase":"PHASE4","title":"Multi-Center PAMPA Study","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Psoriasis","enrollment":176},{"nctId":"NCT05784129","phase":"PHASE3","title":"A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-21","conditions":"Crohn's Disease","enrollment":4},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":"Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis","enrollment":113},{"nctId":"NCT02641730","phase":"PHASE3","title":"An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-12-15","conditions":"Palmoplantar Pustulosis","enrollment":159},{"nctId":"NCT02905331","phase":"PHASE3","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-28","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT03628924","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-04","conditions":"Hidradenitis Suppurativa","enrollment":184},{"nctId":"NCT04914429","phase":"PHASE4","title":"A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-25","conditions":"Psoriasis","enrollment":327},{"nctId":"NCT03158285","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-07-12","conditions":"Arthritis, Psoriatic","enrollment":741},{"nctId":"NCT03998683","phase":"PHASE3","title":"A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2019-09-03","conditions":"Psoriasis","enrollment":117},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03162796","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-08-24","conditions":"Arthritis, Psoriatic","enrollment":383},{"nctId":"NCT03573323","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-09","conditions":"Plaque Psoriasis","enrollment":1027},{"nctId":"NCT03090100","phase":"PHASE3","title":"A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-27","conditions":"Psoriasis","enrollment":1048},{"nctId":"NCT02203032","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-07","conditions":"Psoriasis","enrollment":872},{"nctId":"NCT01484587","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-08-22","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":198,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for guselkumab","genericName":"Placebo for guselkumab","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}